| http://dbpedia.org/ontology/abstract
|
Sitravatinib (MGCD516) is an experimental … Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib is being developed by Mirati Therapeutics. Ongoing phase II trials include a trial for liposcarcoma, a combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma. Sitravatinib is being evaluated in ongoing trials in patients with advanced non-small cell lung cancer, including in a combination trial with nivolumab in those who are resistant to checkpoint inhibitor therapy, and certain patients who are naïve to checkpoint inhibitor therapy.are naïve to checkpoint inhibitor therapy.
|
| http://dbpedia.org/ontology/casNumber
|
1123837-84-2
|
| http://dbpedia.org/ontology/fdaUniiCode
|
CWG62Q1VTB
|
| http://dbpedia.org/ontology/kegg
|
D11140
|
| http://dbpedia.org/ontology/thumbnail
|
http://commons.wikimedia.org/wiki/Special:FilePath/Sitravatinib.svg?width=300 +
|
| http://dbpedia.org/ontology/wikiPageID
|
53059029
|
| http://dbpedia.org/ontology/wikiPageLength
|
4254
|
| http://dbpedia.org/ontology/wikiPageRevisionID
|
1075325734
|
| http://dbpedia.org/ontology/wikiPageWikiLink
|
http://dbpedia.org/resource/Mirati_Therapeutics +
, http://dbpedia.org/resource/Renal_cell_carcinoma +
, http://dbpedia.org/resource/Phase_II_trial +
, http://dbpedia.org/resource/Category:Tyrosine_kinase_inhibitors +
, http://dbpedia.org/resource/Non-small_cell_lung_cancer +
, http://dbpedia.org/resource/Tyrosine_kinase +
, http://dbpedia.org/resource/Nivolumab +
, http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
|
| http://dbpedia.org/property/c
|
33
|
| http://dbpedia.org/property/casNumber
|
1123837
|
| http://dbpedia.org/property/chemspiderid
|
52083477
|
| http://dbpedia.org/property/f
|
2
|
| http://dbpedia.org/property/h
|
29
|
| http://dbpedia.org/property/iupacName
|
N--N′--1,1-cyclopropanedicarboxamide
|
| http://dbpedia.org/property/kegg
|
D11140
|
| http://dbpedia.org/property/n
|
5
|
| http://dbpedia.org/property/o
|
4
|
| http://dbpedia.org/property/s
|
1
|
| http://dbpedia.org/property/smiles
|
COCCNCc1cccc2cc3ccOc4cccNCC5CNc6cccF
|
| http://dbpedia.org/property/stdinchi
|
1
|
| http://dbpedia.org/property/stdinchikey
|
WLAVZAAODLTUSW-UHFFFAOYSA-N
|
| http://dbpedia.org/property/unii
|
CWG62Q1VTB
|
| http://dbpedia.org/property/wikiPageUsesTemplate
|
http://dbpedia.org/resource/Template:Infobox_drug +
, http://dbpedia.org/resource/Template:Reflist +
, http://dbpedia.org/resource/Template:Fdacite +
|
| http://purl.org/dc/terms/subject
|
http://dbpedia.org/resource/Category:Tyrosine_kinase_inhibitors +
, http://dbpedia.org/resource/Category:Experimental_cancer_drugs +
|
| http://www.w3.org/ns/prov#wasDerivedFrom
|
http://en.wikipedia.org/wiki/Sitravatinib?oldid=1075325734&ns=0 +
|
| http://xmlns.com/foaf/0.1/depiction
|
http://commons.wikimedia.org/wiki/Special:FilePath/Sitravatinib.svg +
|
| http://xmlns.com/foaf/0.1/isPrimaryTopicOf
|
http://en.wikipedia.org/wiki/Sitravatinib +
|
| owl:sameAs |
http://yago-knowledge.org/resource/Sitravatinib +
, http://dbpedia.org/resource/Sitravatinib +
, http://www.wikidata.org/entity/Q27275860 +
, https://global.dbpedia.org/id/2YnZa +
|
| rdf:type |
http://dbpedia.org/ontology/Drug +
, http://dbpedia.org/ontology/ChemicalSubstance +
, http://www.ontologydesignpatterns.org/ont/dul/DUL.owl#ChemicalObject +
, http://www.wikidata.org/entity/Q8386 +
|
| rdfs:comment |
Sitravatinib (MGCD516) is an experimental … Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases. Sitravatinib is being developed by Mirati Therapeutics. Ongoing phase II trials include a trial for liposcarcoma, a combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma. Sitravatinib is being evaluated in ongoing trials in patients with advanced non-small cell lung cancer, including in a combination trial with nivolumab in those who are resistant to checkpoint inhibitor therapy, and certain patients who are naïve to checkpoint inhibitor therapy.are naïve to checkpoint inhibitor therapy.
|
| rdfs:label |
Sitravatinib
|
